Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Multiple Myeloma
Clinical trial register · United Kingdom · industry-sponsored

Multiple Myeloma Trials in the UK, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 31 Manchester 15 Oxford 12 Birmingham 11 Cardiff 9
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC13 AbbVie6 GlaxoSmithKline5 Celgene4 Pfizer4
Site city
London31 Manchester15 Oxford12 Birmingham11 Cardiff9
All 50 cities
Target enrolment
to

Multiple Myeloma trials in the UK

44 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Blackpool, Cambridge, Canterbury
2026-09-09
Recruiting
C4 Therapeutics, Inc.
Phase 2
100
London
2026-02-18
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Canterbury, Cardiff, Dundee, London, Nottingham, Portsmouth, Sutton
2026-02-04
Recruiting
Takeda
Phase 3
183
Exeter, Colcester, Gloucester, Cardiff, Milton Keynes, Stafford
2026-01-14
Recruiting
Celgene
Phase 1/2
62
London, Manchester
2025-10-07
Recruiting
AbbVie
Phase 1/2
325
Manchester
2025-07-23
Recruiting
AbbVie
Phase 1/2
602
London, Birmingham, Cardiff
2025-06-30
Recruiting
GlaxoSmithKline
Phase 3
520
Leicester, Middlesbrough, Oxford, Plymouth, Wolverhampton
2024-12-16
Recruiting
Janssen Research & Development, LLC
Phase 2
210
Belfast, Colchester, Eastbourne, Liverpool, London, Manchester, Newcastle upon Tyne
2024-08-26
Active, closed
Kite, A Gilead Company
Phase 3
452
Bristol, Cardiff, Leeds, London, Newcastle
2024-08-23
Active, closed
Janssen Research & Development, LLC
Phase 1
108
London, Manchester, Norwich, Plymouth
2024-06-07
Active, closed
AbbVie
Phase 3
421
Cambridge, Edinburgh, London, Nottingham, Leeds, Manchester
2024-05-19
Recruiting
Pfizer
Phase 3
492
Milton Keynes, Bodelwyddan, Bournemouth, Poole, Eastbourne, Worthing, Birmingham, London
2024-02-08
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Blackpool, Cardiff, Dundee, Leeds, London, Nottingham, Plymouth, Portsmouth
2024-01-22
Active, closed
Celgene
Phase 3
79
Birmingham, London
2023-10-16
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Aberdeen, Windsor, Derby, Bournemouth, Portsmouth, Stoke-on-Trent, Edinburgh, London
2023-06-22
Recruiting
GlaxoSmithKline
Phase 1/2
123
Leicester, Oxford, Plymouth
2023-06-14
Recruiting
AbbVie
Phase 1
210
London, Manchester
2023-03-21
Active, closed
Janssen Research & Development, LLC
Phase 3
213
Leeds, Leicester, Surrey, Wolverhampton
2022-12-15
Recruiting
Pfizer
Phase 3
1,060
Leicester, London, Edinburgh, Oxford, Stoke-on-Trent, Birmingham, Cardiff, Glasgow
2022-11-10
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Edinburgh, London, Wolverhampton
2022-10-25
Recruiting
Bristol-Myers Squibb
Phase 1/2
260
Manchester, Leicester, Liverpool, Oxford, London
2022-10-18
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Blackpool, Dundee, London, Newcastle upon Tyne, Nottingham, Plymouth, Sutton, Wolverhampton
2022-10-13
Active, closed
Celgene
Phase 3
939
Nottingham, Belfast Northern Ireland, Birmingham, Canterbury Kent, Lancashire Blackpool, London, Oxford, Portsmouth
2022-06-23
Active, closed
Pfizer
Phase 3
854
Cambridge, Birmingham, Belfast, Glasgow, Reading, Wolverhampton
2022-03-25
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Blackpool, Dundee, London, Oxford, Plymouth, Sutton
2021-10-14
Recruiting
Pfizer
Phase 3
893
Bournemouth, Oxford, Cardiff, Bristol, Canterbury, Manchester
2021-10-04
Active, closed
Janssen Research & Development, LLC
Phase 1
166
London, Manchester, Oxford, Surrey
2021-09-22
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Birmingham, Bristol, Leeds, London, Manchester, Surrey
2021-08-19
Recruiting
Genentech, Inc.
Phase 1
186
London, Sutton
2021-07-26
Active, closed
Janssen Research & Development, LLC
Phase 1
140
London, Manchester, Surrey
2021-03-12
Active, closed
GlaxoSmithKline
Phase 3
302
London, Plymouth, Southampton, Stoke-on-Trent, Sutton
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Birmingham, Bristol, Cardiff, London, Manchester, Newcastle upon Tyne
2020-06-12
Active, closed
GlaxoSmithKline
Phase 3
325
Airdrie, Dundee, Edinburgh, London, Nottingham, Oxford, Plymouth, Stoke-on-Trent
2020-04-02
Active, closed
GlaxoSmithKline
Phase 1
118
Leicester, Oxford, Southampton
2019-12-18
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Plymouth, Leicester, London, Southampton, Blackpool, Liverpool, Wolverhampton
2019-09-06
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide
CellCentric Ltd.
Phase 1/2
250
Sutton, Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester
2019-08-09
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
387
Sutton
2019-01-23
Active, closed
AbbVie
Phase 3
265
Cambridge, London, Norwich, Nottingham, Glasgow, Stoke-on-Trent, Manchester, Portsmouth
2018-10-22
By invitation
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
NCT03628612Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
Autolus Limited
Phase 2
500
Glasgow, London, Manchester, Newcastle upon Tyne
2018-08-02
Active, closed
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
NCT02952508Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugCLR 131
Cellectar Biosciences, Inc.
Phase 2
120
London
2017-07-26
Active, closed
Celgene
Phase 1/2
466
Birmingham, Leeds, Oxford, Sutton
2016-10-14
Active, closed
Bristol-Myers Squibb
Observational
2,555
Truro, Leeds, Liverpool, Nottingham, Stafford, Swansea
2012-06-13
Rows per page Showing 1–44 of 44
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-uk/condition/multiple-myeloma

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 10 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 44 of those studies listing the condition Multiple Myeloma.

How many Multiple Myeloma trials are recruiting in the UK?

20 of the 44 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 23 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Multiple Myeloma), 44 studies
PhaseStudiesRecruitingShare
Phase 324854.5%
Phase 1/29820.5%
Phase 16213.6%
Phase 2429.1%
Observational102.3%

Most active sponsors

Lead sponsors with the most studies (Multiple Myeloma)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC134
AbbVie63
GlaxoSmithKline52
Celgene41
Pfizer43
Bristol-Myers Squibb31
Autolus Limited10
C4 Therapeutics, Inc.11
CellCentric Ltd.11
Cellectar Biosciences, Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.